Barclays’s Hemab Therapeutics COAG Stock Holding History

Barclays’s Portfolio COAG Stock Details COAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.1K	Buy	+1,011	New	+$27.9K	﹤0.01%	4413

Other funds holding COAG

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's COAG Position: Q2 2026 in Review

Barclays opened a new position in Hemab Therapeutics (COAG) in Q2 2026: 1,011 shares worth $37.1K. The stake represents ﹤0.01% of the portfolio and ranks #4413 among its holdings.

55 funds tracked by Wall St. Rank hold COAG as of Q2 2026.

Barclays held 1,011 shares of Hemab Therapeutics worth $37.1K as of Q2 2026.
Hemab Therapeutics was a new Barclays position in Q2 2026.
Hemab Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4413 holding.
55 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.